Ferrokin Biosciences Inc. offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The firm is a clinical stage biotechnology company dedicated to improving the management of patients with iron overload. They are currently developing a new treatment for transfusional iron overload. Iron overload is caused by chronic transfusion therapy. Patients with inherited anemias such as thalassemia and sickle cell disease require regular transfusions to maintain their health and sense of well-being. Patients with acquired anemias such as myelodysplastic syndrome develop transfusion-dependent anemia later in life. All patients receiving chronic transfusion therapy accumulate iron and may eventually require treatment for iron overload. The firm's lead medicine, FBS0701, is being evaluated in a comprehensive development program as a once-daily treatment in capsule form for patients with transfusional iron overload. In March 2012, irt was announced that Shire PLC had agreed to acquire FerroKin BioSciences Inc.